ReviewFrontiers in immunology2019
Environmental Triggers of Autoreactive Responses: Induction of Antiphospholipid Antibody Formation.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Antiphospholipid antibody-related hepatic vasculitis in a juvenile after non-severe COVID-19: a case report and literature review.Frontiers in immunology · 2024Pooled it
- The role of the intestinal microbiome in antiphospholipid syndrome.Frontiers in immunology · 2022Pooled it
- Antiphospholipid syndrome: epidemiology and outcomes in the evolving criteria era.Nature reviews. Rheumatology · 2026Review
- Characterization of Anti-Phospholipid Antibodies in Lyme Borreliosis Using In-House Developed ELISAs.Antibodies (Basel, Switzerland) · 2026Article
- Ischemic cerebrovascular accident in an HIV patient: Neurosyphilis and antiphospholipid syndromeBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Mechanisms and Therapeutic Implications of Microbiome-Mediated Immune Dysregulation in Recurrent Pregnancy Loss and Implantation Failure.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Cross-Reactivity of Antiphospholipid Antibodies with Gut Commensal Proteins in Antiphospholipid Syndrome.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Genetic factors associated with the co-occurrence of endometriosis with antiphospholipid syndrome (Review).Experimental and therapeutic medicine · 2025Review
- NK cell dysfunction in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- Navigating antiphospholipid syndrome: from personalized therapies to cutting-edge research.Rheumatology advances in practice · 2025Review
- Parvovirus B19 Infection Is Associated with the Formation of Neutrophil Extracellular Traps and Thrombosis: A Possible Linkage of the VP1 Unique Region.International journal of molecular sciences · 2024Article
- Rethinking antiphospholipid syndrome to guide future management and research.Nature reviews. Rheumatology · 2024Review
- Contributions of Synthetic Chemicals to Autoimmune Disease Development and Occurrence.Current environmental health reports · 2024Review
- New Directions in Infection-Associated Ischemic Stroke.Journal of clinical neurology (Seoul, Korea) · 2024Review
- Lupus Anticoagulant Detection under the Magnifying Glass.Journal of clinical medicine · 2023Review
- The spectrum of COVID-19-associated chorioretinal vasculopathy.American journal of ophthalmology case reports · 2023Article
- Autoimmune/inflammatory syndrome induced by adjuvants (ASIA): past, present, and future implications.Clinical and experimental immunology · 2023Review
- The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention.Current opinion in immunology · 2023Review
- Outcomes associated with antiphospholipid antibodies in COVID-19: A prospective cohort study.Research and practice in thrombosis and haemostasis · 2023Article
- Thrombosis and antiphospholipid antibodies in Japanese COVID-19: based on propensity score matching.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid antibodies (aPLs) comprise a diverse family of autoantibodies targeted against proteins with the affinity toward negatively charged phospholipids or protein-phospholipid complexes. Their clinical significance, including prothrombotic potential of anti-cardiolipin antibodies (aCLs), anti-β2-glycoprotein I antibodies (aβ2-GPIs), and lupus anti-coagulant (LA), is well-established. However, the ontogeny of these pathogenic aPLs remains less clear. While transient appearance of aPLs could be induced by various environmental factors, in genetically predisposed individuals these factors may eventually lead to the development of the antiphospholipid syndrome (APS). Since the first description of APS, it has been found that a wide variety of microbial and viral agents influence aPLs production and contribute to clinical manifestations of APS. Many theories attempted to explain the pathogenic potential of different environmental factors as well as a phenomenon termed molecular mimicry between β2-GPI molecule and infection-relevant structures. In this review, we summarize and critically assess the pathogenic and non-pathogenic formation of aPLs and its contribution to the development of APS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.